Zervimesine
| Clinical data | |
|---|---|
| Other names | CT-1812; CT1812 |
| Drug class | Sigma σ2 receptor antagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H33NO4S |
| Molar mass | 431.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zervimesine (INN, USAN;[1] developmental code name CT-1812 or CT1812) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications.[2][3][4]
The drug shows high affinity for the sigma σ2 receptor (Ki = 8.5 nM).[5] It also shows 7.4-fold lower affinity for the sigma σ1 receptor (Ki = 63 nM).[5] Aside from the sigma σ1 receptor, the drug shows 100-fold selectivity for the sigma σ2 receptor over 72 other targets.[5] The sigma σ2 receptor is a binding site for β-amyloid oligomers.[4] Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in both preclinical and clinical studies.[4] As of 2024, effectiveness data on zervimesine for treatment of Alzheimer's disease are still lacking.[4]
Zervimesine is under development by Cognition Therapeutics.[2] As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration.[2] The drug was also being developed for treatment of other cognitive disorders, but development for this indication was discontinued.[2]
See also
References
- ^ "Proposed INN: List 133 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 39 (2). 2025.
- ^ a b c d "Cognition Therapeutics". AdisInsight. 14 July 2025. Retrieved 27 July 2025.
- ^ Kaur G, Dar ZA, Bajpai A, Singh R, Bansal R (2024). "Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist". Clinical Therapeutics. 46 (11): e21–e28. doi:10.1016/j.clinthera.2024.08.013. PMID 39289058. Retrieved 27 July 2025.
- ^ a b c d Thitilertdecha P, Brimson JM (18 October 2024). "CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer's Disease Treatment: A Systematic Review of Available Clinical Data". Journal of Alzheimer's Disease. 101 (s1): S115–S128. doi:10.3233/JAD-230994. PMID 39422939. Retrieved 27 July 2025.
- ^ a b c Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. (August 2021). "Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification". Alzheimers Dement. 17 (8): 1365–1382. doi:10.1002/alz.12302. PMID 33559354.